GlassScriptPhysician profile
Jeffrey B Fischer
NPI 1821095068
$5,234.47
in general payments reported to CMS, 2019-2025
28 companies · $537 in 2025
The $537 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $523 · 2021: $454 · 2022: $723 · 2023: $1,794 · 2024: $512 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,898 · Travel and Lodging: $860 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,897.77 |
| Travel and Lodging | $859.67 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $1,485.37 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Astellas Pharma US INC | $1,255.97 | 2019-2024 | Xtandi, Myrbetriq |
| Pfizer INC. | $513.37 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $436.81 | 2020-2025 | |
| Axonics, INC. | $220.78 | 2021-2024 | Axonics |
| Teleflex LLC | $188.57 | 2021-2025 | Barrigel, Urolift |
| Janssen Biotech, INC. | $185.79 | 2019-2025 | Erleada |
| Inari Medical, INC. | $174.19 | 2020 | |
| Myriad Genetic Laboratories, INC. | $101.05 | 2021-2024 | Prolaris |
| Seagen INC. | $84.99 | 2025 | |
| Neotract INC. | $79.62 | 2019-2020 | |
| Urogen Pharma, INC. | $75.93 | 2022-2024 | Jelmyto |
| Abbvie INC. | $58.44 | 2022-2024 | |
| 180 Medical, INC. | $46.61 | 2020-2023 | Gentlecath |
| Boston Scientific Corporation | $44.15 | 2019-2025 | Axonics |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $41.03 | 2023 | Itind System |
| Sumitomo Pharma America, INC. | $30.04 | 2023 | Gemtesa |
| Tolmar Pharmaceuticals, INC. | $26.07 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $23.59 | 2019 | |
| Ferring Pharmaceuticals INC. | $22.97 | 2024 | Adstiladrin |
| Calyxo, INC. | $21.76 | 2025 | Cvac Aspiration System |
| Tolmar, INC. | $20.98 | 2023 | |
| Karl Storz Endoscopy-America | $20.08 | 2020 | |
| Medtronic USA, INC. | $19.04 | 2020 | |
| Laborie Medical Technologies Corp. | $17.07 | 2024 | Urgent PC Neuromodulation System |
| Antares Pharma, INC. | $14.78 | 2020 | |
| Urovant Sciences INC | $13.82 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Fischer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.